United States Particle Therapy Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Particle Therapy Market reached US$ 1.33 billion in 2024 and is expected to reach US$ 2.58 billion by 2033, growing at a CAGR of 7.9% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/particle-therapy-market?sb

Key Development:

United States: Recent Industry Developments

✅ In December 2025, a landmark Phase III multicenter study published by MD Anderson Cancer Center demonstrated that proton therapy significantly improves survival and reduces toxicity in head and neck cancers, providing the strongest clinical evidence to date for adoption of proton particle therapy in standard oncologic care

✅ In December 2025, Mayo Clinic highlighted plans to build the first carbon ion therapy facility in the Americas inside its Duan Family Building in Florida, aiming to address aggressive, treatment‐resistant cancers with advanced heavy‐ion particle therapy by 2028.

✅ In November 2025, Leo Cancer Care received FDA 510(k) clearance for Marie®, its upright particle therapy system that reimagines treatment delivery with reduced facility footprint and enhanced patient positioning, marking a major regulatory milestone for innovative particle therapy hardware.

✅ In June 2025, Mayo Clinic opened its Duan Family Building in Jacksonville, Florida, a $320 million oncology center that will house the first heavy particle (carbon ion) therapy program in the Americas with proton therapy to follow, expanding access to next‐generation cancer treatments.

✅ In June 2025, Mayo Clinic advanced plans to bring carbon ion and proton therapy to the Western Hemisphere, integrating both modalities in one centre to treat aggressive, treatment‐resistant cancers, representing a strategic investment in cutting‐edge radiation oncology infrastructure.

✅ In May 2025, IBA reported solid commercial momentum in its particle therapy business with a €1.5 billion equipment and services backlog, share buybacks in progress, and strengthened financial positioning, signalling sustained investor confidence in particle therapy tech adoption.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=particle-therapy-market

Japan: Recent Industry Developments

✅ In November 2025, the 5th Annual Asia‐Oceania Particle Therapy Co‐operative Group (PTCOG‐AO) Conference was successfully held in Hong Kong, convening global particle therapy leaders to share technological innovations, clinical advances, and best practices for precision proton and heavy‐ion therapy.

✅ In September 2025, the second proton therapy system at University of Tsukuba Hospital began clinical treatment, featuring advanced spot scanning technology and multi‐gantry treatment rooms under a long‐term consortium operation model, underscoring infrastructure renewal in Japan's particle therapy ecosystem.

✅ In July 2025, Hitachi High‐Tech and partners finalized a contract to build a new proton therapy facility at Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital, with a compact accelerator and dual rotating gantry rooms, reinforcing expansion of state‐of‐the‐art particle therapy services in Greater Tokyo.

✅ In March 2025, IBA signed a term sheet with Apollo Hospitals for Proteus®ONE proton therapy systems (with an option for a second), set to expand access to proton therapy in India and reflecting strategic regional collaboration with a Japanese OEM leader.

✅ In February 2025, IBA contracted with Asian Institute of Gastroenterology (AIG) in India for a Proteus®ONE compact proton therapy system at its Hyderabad oncology campus, exemplifying global deployment of Japanese‐origin accelerator tech in the broader Asia Pacific region.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/particle-therapy-market?sb

Key Players:

=> IBA Worldwide, Siemens Healthcare Private Limited, Hitachi High-Tech Corporation, Mevion Medical Systems, Provision Healthcare, Optivus Proton Therapy, Inc., Sumitomo Heavy Industries, Ltd., ProTom International, B dot Medical Inc., Atlas Copco Group among others.

Emerging Players

=> Panacea, Terapet, and P-Cure among others

Key Segments:

By Type

Proton Therapy - 60% share, widely adopted for precise tumor targeting with minimal damage to surrounding healthy tissue.
Heavy Ion Therapy - 40% share, preferred for radioresistant and complex tumors due to higher biological effectiveness.

By System

Single Room Systems - 45% share, suitable for smaller hospitals and research facilities with limited patient volumes.
Multi-Room Systems - 55% share, deployed in large cancer centers to treat high patient volumes and support research activities.

By Application

Treatment - 70% share, the primary application for clinical patient care across various cancer types.
Clinical Research - 30% share, focused on therapy optimization, novel protocols, and new indications for particle therapy.

By Cancer Type

Pediatric Cancer - 15% share, benefiting from reduced radiation exposure and long-term side effects.
Breast Cancer - 20% share, emerging application in high-precision therapies.
Lung Cancer - 18% share, selected for tumors near critical structures like the heart or spinal cord.
Neck Cancer - 12% share, increasingly treated with particle therapy to protect vital organs.
Others - 35% share, includes prostate, brain, and gastrointestinal cancers.

By End-User

Hospitals - 60% share, primary adopters providing both treatment and clinical services.
Cancer Research Centers - 25% share, focusing on clinical trials and advanced therapy research.
Others - 15% share, includes specialty clinics and academic institutions.

By Region

North America - 40% share, strong infrastructure, technology adoption, and patient awareness.
Europe - 30% share, led by Germany, France, and the U.K., with advanced cancer centers.
Asia-Pacific - 20% share, growing rapidly due to rising cancer incidence and healthcare investments.
South America - 5% share, limited adoption but expanding in Brazil and Argentina.
Middle East & Africa - 5% share, emerging market with government-backed oncology initiatives.

FAQ

What is the current size of the Particle Therapy Market?

A: In 2024, the Particle Therapy Market was valued at US$ 1.33 billion, reflecting its strong industry presence.

Q2: How large is the Particle Therapy Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Particle Therapy Market will grow to around US$ 2.58 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Particle Therapy Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.9% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.